ArticleJournal of arrhythmia2022

Impact of three major risk factors on clinical outcomes in patients with nonvalvular atrial fibrillation receiving rivaroxaban: Sub-analysis from the XAPASS study.

Takanori Ikeda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.